Cigna Group (CI) director Eric J. Foss receives grant of 782 shares

Rhea-AI Filing Summary

Cigna Group director Eric J. Foss received a grant of 782 shares of common stock on April 22, 2026. The shares were acquired at no cost as a compensation-related award and are held directly. Following this grant, Foss directly owns 36,696 shares of Cigna common stock.

Insights

Equity compensation analyst

Routine director stock grant with modest size and no open‑market trading.

Eric J. Foss, a director of Cigna Group, received 782 shares of common stock as a grant with a reported price of $0.0000 per share, indicating a compensation award rather than a market purchase.

The filing shows Foss holding 36,696 shares after the grant, so this award modestly increases an existing equity position. With no sales, exercises, or derivative positions reported, this appears to be a standard, low-impact governance and compensation event.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider FOSS ERIC J

Role null

Type	Security	Shares	Price	Value
Grant/Award	Common Stock, $.01 Par Value	782	$0.00	--

Holdings After Transaction: Common Stock, $.01 Par Value — 36,696 shares (Direct, null)

Footnotes (1)

Key Figures

Shares granted: 782 shares Reported grant price: $0.0000 per share Shares owned after grant: 36,696 shares +1 more

4 metrics

Shares granted 782 shares Common Stock grant on April 22, 2026

Reported grant price $0.0000 per share Compensation-related award, not market purchase

Shares owned after grant 36,696 shares Total direct holdings following transaction

Transaction code A Grant, award, or other acquisition

Key Terms

Common Stock, $.01 Par Value, Grant, award, or other acquisition, Form 4, transaction code

4 terms

Common Stock, $.01 Par Value financial

"security_title: Common Stock, $.01 Par Value"

Grant, award, or other acquisition financial

"transaction_code_description: Grant, award, or other acquisition"

Form 4 regulatory

"INSIDER FILING DATA (Form 4):"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

transaction code regulatory

"transaction_code_description: Grant, award, or other acquisition"

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

FOSS ERIC J

(Last) (First) (Middle)

900 COTTAGE GROVE ROAD

(Street)

BLOOMFIELD CONNECTICUT 06002

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Cigna Group [ CI ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/22/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock, $.01 Par Value	04/22/2026		A		782	A	$0	36,696	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

Exhibit 24 - Power of Attorney

	Tyler Gratton, attorney-in-fact	04/24/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Cigna Group (CI) director Eric J. Foss report in this Form 4?

Eric J. Foss reported receiving a grant of 782 Cigna Group common shares. The award was recorded at a price of $0.0000 per share and increased his direct holdings to 36,696 shares, reflecting routine equity-based director compensation rather than open-market trading.

How many Cigna Group (CI) shares does Eric J. Foss hold after this transaction?

After the reported grant, Eric J. Foss directly holds 36,696 Cigna Group common shares. This total includes the 782-share award reported in the filing and represents his post-transaction ownership as disclosed, with no derivative securities listed in the same report.

Was the Cigna Group (CI) Form 4 transaction a market purchase or a stock grant?

The Form 4 shows a stock grant, not a market purchase. The transaction is coded as a grant, award, or other acquisition with 782 shares at $0.0000 per share, indicating compensation-related equity rather than an open-market buy or sell by the director.

Does the Cigna Group (CI) Form 4 show any stock sales by Eric J. Foss?

The Form 4 does not report any stock sales by Eric J. Foss. It only shows an acquisition of 782 common shares as a grant, bringing his total direct holdings to 36,696 shares, with no disposals, option exercises, or derivative transactions listed in this filing.

What does transaction code A mean in the Cigna Group (CI) Form 4?

Transaction code A in this Form 4 denotes a grant, award, or other acquisition of shares. For Eric J. Foss, it reflects a 782-share stock grant at a reported price of $0.0000 per share, typical of equity compensation for directors rather than trading activity.